Financial Data
ITCI Financial Data
Revenue · Earnings · Margins · Balance Sheet · Cash Flow
ITCIIntra-Cellular Therapies, Inc.
Healthcare / Drug Manufacturers - Specialty & Generic
Low Priority
In Line With Peers
Latest quote
- Momentum—
- Value34
- Quality60
- Risk resilience82
- Sentiment—
Financial Data Overview
Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.
Quarterly Financial Statements
Updated Oct 31, 2026.
| Metric | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $199.22M | $175.16M | $161.39M | $144.87M | $131.51M | $125.81M | $110.13M | $94.73M |
| Gross Profit | $178.82M | $159.86M | $150.03M | $134.97M | $120.8M | $116.68M | $102.97M | $87.98M |
| Operating Income | -$29.2M | -$38.85M | -$27.72M | -$20.95M | -$34.1M | -$29.71M | -$47.18M | -$48.39M |
| Net Income | -$16.89M | -$26.32M | -$16.22M | -$15.25M | -$28.58M | -$24.26M | -$42.78M | -$44.05M |
| EPS | $0.56 | -$0.25 | -$0.16 | -$0.16 | -$0.3 | -$0.25 | -$0.45 | -$0.46 |
| Metric | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.08M | -$26.53M | $542K | -$34.12M | -$2.06M | -$25.27M | -$36.8M | -$60.07M |
| Capital Expenditure | $427K | -$696K | -$53K | $0 | -$1K | -$268K | $0 | $0 |
| Free Cash Flow | -$12.65M | -$27.22M | $489K | -$34.12M | -$2.06M | -$25.54M | -$36.8M | -$60.07M |
| Net Cash Provided By Operating Activities | -$13.08M | -$26.53M | $542K | -$34.12M | -$2.06M | -$25.27M | -$36.8M | -$60.07M |
| Metric | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
|---|---|---|---|---|---|---|---|
| Total Assets | $1.37B | $1.32B | $1.32B | $747.04M | $728.3M | $717.66M | $713.6M |
| Total Debt | $16.98M | $17.71M | $18.29M | $16.38M | $16.94M | $17.48M | $17.99M |
| Cash And Cash Equivalents | — | — | — | — | — | — | — |
| Total Liabilities | $218.45M | $179.62M | $175.89M | $147.54M | $136.87M | $116.98M | $106.51M |
| Total Stockholders Equity | $1.15B | $1.14B | $1.14B | $599.5M | $591.42M | $600.68M | $607.09M |
| Metric | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio | 37.29 | -73.17 | -106.23 | -106.67 | -59.68 | -52.09 | -35.18 | -29.43 |
| P/B ratio | 7.5 | 6.76 | 6.16 | 11.03 | 11.66 | 8.34 | 10.01 | 8.21 |
| P/S ratio | 43.24 | 44.18 | 43.7 | 45.65 | 52.44 | 39.81 | 55.17 | 54.38 |
| Debt To Equity | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Free Cash Flow Yield | -0.15% | -0.35% | 0.01% | -0.52% | -0.03% | -0.51% | -0.61% | -1.17% |
| Metric | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio | 37.29 | -73.17 | -106.23 | -106.67 | -59.68 | -52.09 | -35.18 | -29.43 |
| P/B ratio | 7.5 | 6.76 | 6.16 | 11.03 | 11.66 | 8.34 | 10.01 | 8.21 |
| P/S ratio | 43.24 | 44.18 | 43.7 | 45.65 | 52.44 | 39.81 | 55.17 | 54.38 |
| Return On Equity | -1.47% | -2.30% | -1.42% | -2.54% | -4.83% | -4.04% | -7.05% | -7.02% |
| Debt To Equity | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Current Stock Metrics
Current fundamental, technical, and risk readings in one place.
| Metric | Value |
|---|---|
| Pe | -183.15x |
| Pb | 11.84x |
| Revenue Growth Yoy | 51.49% |
| EPS Growth Yoy | 286.67% |
| Gross Margin | 91.63% |
| Operating Margin | -17.14% |
| ROE | -8.58% |
| ROIC | -9.98% |
| Debt To Equity | 0.01 |
| FCF Yield | -0.52% |
As of Oct 29, 2026
| Metric | Value |
|---|---|
| Close | $131.87 |
| Volume | 16.04M |
As of Oct 29, 2026
| Metric | Value |
|---|---|
| Resilience score | 82/100 |
| Beta | 0.46 |
As of Oct 29, 2026
Detailed Metrics
Additional measures remain available here while the decision pages stay focused.
No additional fundamental metrics are available.
No additional technical indicators are available.
No additional risk measures are available.
Related Links
ITCI Financial Data FAQ
What is Intra-Cellular Therapies, Inc.'s revenue?
Intra-Cellular Therapies, Inc.'s revenue is one of the core financial data points for ITCI. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.
Is Intra-Cellular Therapies, Inc.'s revenue growing?
Revenue growth shows whether Intra-Cellular Therapies, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.
What is ITCI's EPS?
ITCI's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.
What is Intra-Cellular Therapies, Inc.'s net income?
Intra-Cellular Therapies, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.
How much free cash flow does Intra-Cellular Therapies, Inc. generate?
Free cash flow shows how much cash Intra-Cellular Therapies, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.
How much cash and debt does Intra-Cellular Therapies, Inc. have?
Cash and debt help frame ITCI's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.